This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September quarter revenue falls 12.6%, profit after tax falls 46.7%
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Smallcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended September 30, 2026, revenue from operations was Rs 449.66 crore versus Rs 514.27 crore a year ago, down 12.6%, while profit after tax was Rs 51.63 crore versus Rs 96.85 crore, down 46.7%. EBITDA margin fell to 21.7% from 30.2%. For the consolidated half year ended September 30, 2026: revenue Rs 1,091.23 crore; profit after tax Rs 199.30 crore. Board approved about Rs 47.1 crore for land, funded internally.
Lower revenue, profit and margins may pressure earnings, but positive half-year operating cash flow and planned land expansion provide support.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹449.7 Cr | ₹514.3 Cr | −12.6% |
| Operating profit | ₹61.48 Cr | ₹127.6 Cr | −51.8% |
| Profit after tax | ₹51.63 Cr | ₹96.85 Cr | −46.7% |
| EBITDA margin | 21.7% | 30.3% | −8.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.